ChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $2.07

Shares of ChromaDex Co. (NASDAQ:CDXC) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.07 and traded as high as $3.85. ChromaDex shares last traded at $3.83, with a volume of 126,201 shares trading hands.

Analyst Upgrades and Downgrades

CDXC has been the subject of several research reports. StockNews.com initiated coverage on shares of ChromaDex in a report on Sunday, March 3rd. They set a “strong-buy” rating for the company. Roth Mkm increased their price objective on shares of ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, April 9th.

ChromaDex Stock Up 2.1 %

The stock has a fifty day simple moving average of $3.22 and a 200 day simple moving average of $2.07. The firm has a market capitalization of $289.26 million, a P/E ratio of -54.71 and a beta of 1.96.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CDXC. Gamco Investors INC. ET AL lifted its holdings in ChromaDex by 26.5% in the 3rd quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company’s stock worth $379,000 after purchasing an additional 54,500 shares in the last quarter. Gabelli Funds LLC increased its position in shares of ChromaDex by 9.1% during the 3rd quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock valued at $263,000 after purchasing an additional 15,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of ChromaDex by 121.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after purchasing an additional 45,618 shares during the last quarter. Silverberg Bernstein Capital Management LLC bought a new position in shares of ChromaDex during the 4th quarter valued at approximately $118,000. Finally, International Assets Investment Management LLC increased its position in shares of ChromaDex by 43.0% during the 4th quarter. International Assets Investment Management LLC now owns 28,600 shares of the company’s stock valued at $410,000 after purchasing an additional 8,600 shares during the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.